Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 06, 2025, titled "Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has received approval from Health Canada to market Liothyronine tablets in two strengths — 5 mcg and 25 mcg. Liothyronine is a synthetic thyroid hormone used to treat conditions such as hypothyroidism and goitre, and is the generic equivalent of a widely prescribed medication. With this approval, Zydus can now sell this product in the Canadian pharmaceutical market, expanding its international generic portfolio. The announcement was shared with the stock exchange via a press release dated October 6, 2025. This adds to the company's growing footprint in regulated markets beyond India and the US.
This is a positive development for shareholders as it marks entry into the Canadian market with a niche but steady-demand product, supporting long-term international revenue growth. The immediate stock price impact is likely to be modest given the small size of the Canadian thyroid drug market relative to Zydus's overall business.